Phase 4Terminated

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes

Sponsor
Theratechnologies (Industry)
Enrollment
129 enrolled
Conditions
Diabetic Retinopathy; HIV
Interventions
Tesamorelin; Placebo-Control
Ages
adults, older adults
Registry
NCT01591902

Full record on ClinicalTrials.gov

From the registry

To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).

Primary outcomes

  • Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered